Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury
X Wang, BE Figueroa, IG Stavrovskaya, Y Zhang… - Stroke, 2009 - Am Heart Assoc
Stroke, 2009•Am Heart Assoc
Background and Purpose—The identification of a neuroprotective drug for stroke remains
elusive. Given that mitochondria play a key role both in maintaining cellular energetic
homeostasis and in triggering the activation of cell death pathways, we evaluated the
efficacy of newly identified inhibitors of cytochrome c release in hypoxia/ischemia induced
cell death. We demonstrate that methazolamide and melatonin are protective in cellular and
in vivo models of neuronal hypoxia. Methods—The effects of methazolamide and melatonin …
elusive. Given that mitochondria play a key role both in maintaining cellular energetic
homeostasis and in triggering the activation of cell death pathways, we evaluated the
efficacy of newly identified inhibitors of cytochrome c release in hypoxia/ischemia induced
cell death. We demonstrate that methazolamide and melatonin are protective in cellular and
in vivo models of neuronal hypoxia. Methods—The effects of methazolamide and melatonin …
Background and Purpose— The identification of a neuroprotective drug for stroke remains elusive. Given that mitochondria play a key role both in maintaining cellular energetic homeostasis and in triggering the activation of cell death pathways, we evaluated the efficacy of newly identified inhibitors of cytochrome c release in hypoxia/ischemia induced cell death. We demonstrate that methazolamide and melatonin are protective in cellular and in vivo models of neuronal hypoxia.
Methods— The effects of methazolamide and melatonin were tested in oxygen/glucose deprivation–induced death of primary cerebrocortical neurons. Mitochondrial membrane potential, release of apoptogenic mitochondrial factors, pro–IL-1β processing, and activation of caspase -1 and -3 were evaluated. Methazolamide and melatonin were also studied in a middle cerebral artery occlusion mouse model. Infarct volume, neurological function, and biochemical events were examined in the absence or presence of the 2 drugs.
Results— Methazolamide and melatonin inhibit oxygen/glucose deprivation–induced cell death, loss of mitochondrial membrane potential, release of mitochondrial factors, pro–IL-1β processing, and activation of caspase-1 and -3 in primary cerebrocortical neurons. Furthermore, they decrease infarct size and improve neurological scores after middle cerebral artery occlusion in mice.
Conclusions— We demonstrate that methazolamide and melatonin are neuroprotective against cerebral ischemia and provide evidence of the effectiveness of a mitochondrial-based drug screen in identifying neuroprotective drugs. Given the proven human safety of melatonin and methazolamide, and their ability to cross the blood-brain-barrier, these drugs are attractive as potential novel therapies for ischemic injury.
Am Heart Assoc